Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 75

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 75
---
 the clinical
trial program will continue to consume cash resources without generating revenues. There is no guarantee that will be successful in obtaining
an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms.

Foreign Exchange Risks

Our financial statements
are denominated in U.S. dollars and financial results are denominated in U.S. dollars, while a significant portion of our business is
conducted, and a substantial portion of our operating expenses are payable, in currencies other than the U.S. dollar.

Exchange rate fluctuations
may have an adverse impact on our future revenues, if any, or expenses as presented in the financial statements. We may in the future
use financial instruments, such as forward foreign currency contracts, in its management of foreign currency exposure. These contracts
would primarily require us to purchase and sell certain foreign currencies with or for U.S. dollars at contracted rates. We may be exposed
to a credit loss in the event of non-performance by the counterparties of these contracts. In addition, these financial instruments may
not adequately manage our foreign currency exposure. Our results of operations could be adversely affected if we are unable to successfully
manage currency fluctuations in the future.

Effects of Inflation

Inflation generally
affects Revium by increasing its research and development expenses. Revium does not believe that inflation and changing prices had a
significant impact on its results of operations for any periods presented herein, but may have a significant, adverse impact in 2025.

Known Trends, Events and Uncertainties

Potential Impact of the Uncertainty Regaring the Yissum Option on Our Development Plans and Intangible Asset Values

As of the date of this prospectus, we continue
to evaluate the potential implications of the disagreement with Yissum regarding whether the option exercise period for the
Nano-Candesartan (ARB) program has commenced or expired. Under our option agreement with Yissum, the 90-day option period to negotiate
an exclusive license is triggered only upon Yissum’s delivery of a final scientific report summarizing four specified preclinical
studies. We do not believe that such a final scientific report, as defined in the agreement, has been delivered, and certain data and
analyses that we expected to receive remain outstanding. In addition, research activities continued throughout 2024 and 2025 with the
knowledge and involvement of Yissum and University personnel, which contributed to our understanding that the option exercise period
had not begun.

In November 2025